Induction of Labor Affected Fetus / NewbornPhase 1NCT03658590
Dexamethasone and Induction of Delivery
A Phase 1 study testing Dexamethasone and Distilled Water in people with Induction of Labor Affected Fetus / Newborn, run by samar sayed el sayed at 1 site in Egypt.
Trial summary
This study aims to evaluate the effect of intravenous injection of a single dose of dexamethasone in shortening the duration interval between initiation of labor induction and delivery of the fetus in primigravida full-term pregnancy. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Induction of Labor Affected Fetus / Newborn
- What is being tested?
- Dexamethasone and Distilled Water
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 102 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2018to 30 Jun 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Primiparity
- Singleton pregnancy
- Gestational age i.e. 40 weeks or more by date or 1sttrimestric ultrasound.
- Bishop score of 4 or greater.
- Longitudinal lie.
- Vertex presentation.
- Intact membranes
Who cannot join
- Refused consent
- Malpresentation.
- Multiple pregnancies.
- Active phase of labour.
- Rupture of membranes (ROM).
- Cephalo-pelvic disproportion.
Show all 13Show fewer
- Previous C-section or myomectomy operation.
- Known contraindication or hypersensitivity to Dexamethasone.
- Fetal distress.
- IUFD
- Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.
- Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.
- Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Dexamethasone Effect on Induction Delivery Interval at Term Randomized Controlled Trial
This study aims to evaluate the effect of intravenous injection of a single dose of dexamethasone in shortening the duration interval between initiation of labor induction and delivery of the fetus in primigravida full-term pregnancy.
Read the detailed description
Research hypothesis:
In full term primigravidae undergoing induction of labor, the use of a single dose of dexamethasone (8mg) intra-venously will help in shortening the duration interval between initiation of labor induction and delivery of the fetus.
Research question:
In full term primigravidae undergoing induction of labor, does the use of intra-venous dexamethasone play a role in shortening the duration interval between initiation of labor induction and delivery of the fetus?
Patients and Methods
Type of study:
Double blind randomized controlled trial.
Study settings:
Site: Ain Shams Maternity Hospital Study duration: 6 months
Study population:
One hundred and two pregnant women will be recruited in this study from women attending the emergency room department of obstetrics and gynecology at Ain Shams University.
Inclusion criteria:
Primiparity Singleton pregnancy Gestational age i.e. 40 weeks or more by date or 1st trimestric ultrasound. Bishop score of 4 or greater. Longitudinal lie. Vertex presentation. Intact membranes
Exclusion criteria:
Refused consent Malpresentation. Multiple pregnancies. Active phase of labour. Rupture of membranes (ROM). Cephalo-pelvic disproportion. Previous C-section or myomectomy operation. Known contraindication or hypersensitivity to Dexamethasone. Fetal distress. IUFD Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.
Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.
Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.
These criteria will be assessed at first during the initial evaluation in the delivery suite as follows:
History:
Personal, menstrual, obstetric, past and family history will be taken. History of present pregnancy will be taken including the first day of last menstrual period, duration of pregnancy, warning symptoms as headache, visual symptoms, edema of face and fingers, excessive vomiting, heart burn, epigastric pain, vaginal bleeding, decreased fetal movements, edema of the lower limbs and history of any drug intake.
Examination:
- General examination:vital signs, chest, heart and lower limb examination.
- Abdominal examination: for assessment of fundal level, presentation, expected fetal weight, fetal heart rate and presence of scars of previous operations as cesarean section or myomectomy.
- Vaginal examination: for assessment of cervical dilatation and effacement at the beginning, state of fetal membranes, station of fetal head, position of fetal head and pelvic adequacy.
Investigations:
- Laboratory: blood grouping, Rh typing, complete blood count.
- Abdominal ultrasound: to confirm the gestational age, fetal number, viability, presentation, position, estimated fetal weight, and to detect the grade of placental maturity, amount and turbidity of liquor.
- CTG: application of CTG half an hour to all participates before starting any intervention.
Enrollment and Allocation of the patients:
After approval of health ethical committee in Ain Shams Hospital and after the initial evaluation, women who fulfilled the appropriate inclusion and exclusion criteria will be invited to participate in the study, a verbal consent will be obtained from each candidate after explanation of the procedure in details.
Randomization:
The eligible 102 women will be randomized into one of the following two groups:
- Group D (study group): including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
- Group P (control group): including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
No cervical ripping agent will be used for induction of labor in either group. Randomization is performed using a computer-generated randomization system. 102 opaque envelopes will be numbered serially; each envelope will contain the corresponding letter in the randomization table, and when the first pregnant woman arrived, the first envelope will be opened and the pregnant woman will be allocated to the group according to the inside letter.
- Being tested
- Dexamethasone, Distilled Water
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DexamethasoneDrug
Also called Drug group
a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
Distilled WaterDrug
Also called Placebo group
a prefilled syringe with two milliliters of distilled water intravenously.
| Study group | Role | What they receive |
|---|---|---|
| Group D | Active comparator | including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously. Receives: Drug: Dexamethasone |
| Group P | Placebo comparator | including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously. Receives: Drug: Distilled Water |
What is being measured
The primary outcome is the main question the study is designed to answer.
The interval between the initiation of induction and the delivery of the fetus.
Mean time of interval between the initiation of induction and the delivery of the fetus in the two groups.
Measured: Up to 1 day
Secondary outcomes (5)
The duration of the first stage of labor (Partographic representation will do for each participant).
Mean time of duration of the first stage of labor in the two groups.
Measured: Up to 1 hour
The duration of the second stage of labor.
Mean time of duration of the second stage of labor in the two groups.
Measured: Up to 2 hours
The duration of the third stage of labor.
Mean time of duration of the third stage of labor in the two groups.
Measured: Up to 30 minutes
The neonatal outcome by APGAR score.
Mean of APGAR score at 1 and 5 minutes for fetus in the two groups.
Measured: at 1 and 5 minutes
Any postpartum maternal adverse effects (e.g. vital sing abnormality, any maternal postpartum hemorrhage and central nervous system manifestation).
Percentage of postpartum adverse effects in both group.
Measured: Up to 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2018
- Study start1 Jan 2018
- Primary completion15 Apr 2018
- Study completion30 Jun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Induction of Labor Affected Fetus / NewbornStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 102 participants (actual)
Sponsor and investigators
- Lead sponsor
- samar sayed el sayed
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, samar sayed el sayed, Ain Shams University
- Investigators
- Tarek F Tamara, MD, Study chair, Ain Shams UniversityAmgad E Abou Gamrah, MD, Study director, Ain Shams UniversityGihan E Elhawwary, MD, Principal investigator, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03658590
- Sponsor's protocol ID
- 100
- Status last verified
- Sep 2018
- First submitted
- 29 Aug 2018
- Last updated
- 5 Sep 2018
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dexamethasone Effect on Induction Delivery Interval at Term Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT03658590
- Acronym / sponsor ID
- 100
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 102 participants (actual)
- Lead sponsor
- samar sayed el sayedUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 15 Apr 2018 (actual)
- Study completion
- 30 Jun 2018 (actual)
- First posted
- 5 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effect of intravenous injection of a single dose of dexamethasone in shortening the duration interval between initiation of labor induction and delivery of the fetus in primigravida full-term pregnancy.
Detailed description
Research hypothesis:
In full term primigravidae undergoing induction of labor, the use of a single dose of dexamethasone (8mg) intra-venously will help in shortening the duration interval between initiation of labor induction and delivery of the fetus.
Research question:
In full term primigravidae undergoing induction of labor, does the use of intra-venous dexamethasone play a role in shortening the duration interval between initiation of labor induction and delivery of the fetus?
Patients and Methods
Type of study:
Double blind randomized controlled trial.
Study settings:
Site: Ain Shams Maternity Hospital Study duration: 6 months
Study population:
One hundred and two pregnant women will be recruited in this study from women attending the emergency room department of obstetrics and gynecology at Ain Shams University.
Inclusion criteria:
Primiparity Singleton pregnancy Gestational age i.e. 40 weeks or more by date or 1st trimestric ultrasound. Bishop score of 4 or greater. Longitudinal lie. Vertex presentation. Intact membranes
Exclusion criteria:
Refused consent Malpresentation. Multiple pregnancies. Active phase of labour. Rupture of membranes (ROM). Cephalo-pelvic disproportion. Previous C-section or myomectomy operation. Known contraindication or hypersensitivity to Dexamethasone. Fetal distress. IUFD Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.
Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.
Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.
These criteria will be assessed at first during the initial evaluation in the delivery suite as follows:
History:
Personal, menstrual, obstetric, past and family history will be taken. History of present pregnancy will be taken including the first day of last menstrual period, duration of pregnancy, warning symptoms as headache, visual symptoms, edema of face and fingers, excessive vomiting, heart burn, epigastric pain, vaginal bleeding, decreased fetal movements, edema of the lower limbs and history of any drug intake.
Examination:
- General examination:vital signs, chest, heart and lower limb examination.
- Abdominal examination: for assessment of fundal level, presentation, expected fetal weight, fetal heart rate and presence of scars of previous operations as cesarean section or myomectomy.
- Vaginal examination: for assessment of cervical dilatation and effacement at the beginning, state of fetal membranes, station of fetal head, position of fetal head and pelvic adequacy.
Investigations:
- Laboratory: blood grouping, Rh typing, complete blood count.
- Abdominal ultrasound: to confirm the gestational age, fetal number, viability, presentation, position, estimated fetal weight, and to detect the grade of placental maturity, amount and turbidity of liquor.
- CTG: application of CTG half an hour to all participates before starting any intervention.
Enrollment and Allocation of the patients:
After approval of health ethical committee in Ain Shams Hospital and after the initial evaluation, women who fulfilled the appropriate inclusion and exclusion criteria will be invited to participate in the study, a verbal consent will be obtained from each candidate after explanation of the procedure in details.
Randomization:
The eligible 102 women will be randomized into one of the following two groups:
- Group D (study group): including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
- Group P (control group): including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
No cervical ripping agent will be used for induction of labor in either group. Randomization is performed using a computer-generated randomization system. 102 opaque envelopes will be numbered serially; each envelope will contain the corresponding letter in the randomization table, and when the first pregnant woman arrived, the first envelope will be opened and the pregnant woman will be allocated to the group according to the inside letter.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group D | Active comparator | Drug: Dexamethasoneincluding 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously. |
| Group P | Placebo comparator | Drug: Distilled Waterincluding 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- Primiparity
- Singleton pregnancy
- Gestational age i.e. 40 weeks or more by date or 1sttrimestric ultrasound.
- Bishop score of 4 or greater.
- Longitudinal lie.
Key exclusion criteria (13 listed)
- Refused consent
- Malpresentation.
- Multiple pregnancies.
- Active phase of labour.
- Rupture of membranes (ROM).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DexamethasoneAlso: Drug groupa prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously | Drug | Group D |
| Distilled WaterAlso: Placebo groupa prefilled syringe with two milliliters of distilled water intravenously. | Drug | Group P |
Primary outcome
The interval between the initiation of induction and the delivery of the fetus.
Time frame: Up to 1 day
Mean time of interval between the initiation of induction and the delivery of the fetus in the two groups.
5 secondary outcomes
The duration of the first stage of labor (Partographic representation will do for each participant).
Time frame: Up to 1 hour
The duration of the second stage of labor.
Time frame: Up to 2 hours
The duration of the third stage of labor.
Time frame: Up to 30 minutes
The neonatal outcome by APGAR score.
Time frame: at 1 and 5 minutes
Any postpartum maternal adverse effects (e.g. vital sing abnormality, any maternal postpartum hemorrhage and central nervous system manifestation).
Time frame: Up to 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2018.
- Individual participant dataSharing planned: Undecided
Related trials for Induction of Labor Affected Fetus / Newborn
Active, not recruitingPhase 4
The Stimulation To Induce Mothers Study
Oxytocin, Labor Pain
Recruiting
Castor Oil Ingestion and Balloon Catheter for Labor Induction in Nulliparous
Induction of Labor Affected Fetus / Newborn
Recruiting
Cervical Ripening as an Outpatient Method Using the Foley (COMFORT)
Induction of Labor Affected Fetus / Newborn
Active, not recruiting
Induction ATAD Catheter and Lower Segment Thickness
Induction of Labor Affected Fetus / Newborn
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tarek F Tamara, MD study chair
Ain Shams University
Amgad E Abou Gamrah, MD study director
Ain Shams University
Gihan E Elhawwary, MD principal investigator
Ain Shams University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Dexamethasone and Distilled Water in people with Induction of Labor Affected Fetus / Newborn, run by samar sayed el sayed at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The interval between the initiation of induction and the delivery of the fetus. (time frame: Up to 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2018.